Email this article The treatment pathomorphism assessment of prostate cancer afterthe hormonal therapy
- Authors: Poletaeva SV1, Poletaeva SV1
-
Affiliations:
- Самарский государственный медицинский университет
- Issue: Vol 12, No 5-6 (2012)
- Pages: 282-287
- Section: Articles
- URL: https://ogarev-online.ru/2410-3764/article/view/25685
- DOI: https://doi.org/10.17816/2072-2354.2012.0.5-6.282-287
- ID: 25685
Cite item
Full Text
Abstract
For the purpose of studying treatment effects of neoadjuvant androgen deprivation in prostate cancer, histological material from 130 patients are examined. 30 patients had received hormonal treatment before radical prostatectomy. All patients were undergone TRUS-guided 12-cores biopsy. Histological, computer morphometry, immunohistochemical methods were used. Rate of (+) surgical margin in group with the hormonal treatment was 13%, in the control group - 17%. The response to androgen deprivation was variable, with areas of the cancer appearing unaffected. The important task is to identify the grade of treatment effects, because the therapy depends on it.
About the authors
S V Poletaeva
Самарский государственный медицинский университетСамарский государственный медицинский университет
S V Poletaeva
References
- Abbas F., Scardino P.T. Why neoadjuvant androgen deprivation prior to radical prostatectomy is unnecessary. Urol. Clin. North Am. 1996; 23: 587-604.
- Bazinet M., Zheng W., Begin L.R. Morphologic changes induced by neoadjuvant androgen ablation may result in underdetection of positive surgical margins and capsular involvement by prostatic adenocarcinoma. Urology, 1997; 49: p.721-25.
- Ferguson J., Zincke H., Ellison E. Decrease of prostatic untraepithelial neoplasia (PIN) following androgen deprivation therapy in patients with stage T3 carcinoma treated by radical prostatectomy. Urology, 1994; 44: p.91-95.
- Montironi R., Bartels P.H., Thompson D. Androgen-deprived prostate adenocarcinoma: evaluation of treatment-related changes versus no distinctive treatment effect with a Batesin Belief network. Eur. Urology 1996; 30: p. 307-15.
- Montironi R., Magi Galluzzi, Muzzonigro G. Effect of combination endocrine therapy (LHRH agonist and flutamide) on normal prostate, Prostatic Intraepithelial Neoplasia and prostatic adenocarcinoma. J. Clin. Pathology, 1994; 47: p.906-13
- Reuter V.E. Pathological changes in benign and malignant prostatic tissue following androgen deprivation therapy. Urology, 1997; 49 (Suppl 3A): p.16-22.
- Van de Voorde W.M., Elgamal A.A., Van Poppel H.P. Morphologic and immunohistochemical changes in prostate cancer after preoperative hormonal therapy. Cancer, 1994; 74: p.3164-75.
- Shulman C.C., Wildschultz T., Zlotta A.R. Neoadjuvant hormonal treatment prior to radical prostatectomy: facts and questions. Eur. Urology 1997; 32: p. 41-7.
Supplementary files
